Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. has shown a promising outlook due to the successful outcomes of the ReVeRA study, which highlighted statistically significant improvements in patient-reported symptom relief and PSVT conversion rates, indicating strong clinical efficacy for etripamil. The company is further positioned to capitalize on this momentum with an FDA-agreed streamlined Phase 3 program for atrial fibrillation, suggesting a pathway to expedited regulatory approval and an effective commercial launch. Additionally, Milestone's planned presence at major cardiovascular conferences in 2025 is likely to enhance public engagement and support, potentially driving substantial shareholder value in the near-term.

Bears say

Milestone Pharmaceuticals faces a negative outlook primarily due to the competitive landscape in the treatment of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR), where existing oral therapies like beta-blockers may offer delayed relief. The company’s reliance on etripamil could be challenged by the low adoption rates of catheter ablation among eligible patients, limiting the market for medication-based management, which is essential for those who do not seek invasive procedures. Additionally, despite the reported efficacy of etripamil in achieving rapid heart rate reduction, the underappreciation of its market potential and serious patient needs suggests that the current valuation of MIST shares might not reflect an optimistic growth trajectory.

MIST has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 6 analysts, MIST has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.